1.44
0.04 (3.23%)
| Previous Close | 1.40 |
| Open | 1.40 |
| Volume | 1,488,667 |
| Avg. Volume (3M) | 1,301,492 |
| Market Cap | 574,822,912 |
| Price / Sales | 338.25 |
| Price / Book | 97.15 |
| 52 Weeks Range | |
| Earnings Date | 9 Nov 2026 |
| Operating Margin (TTM) | -17,994.78% |
| Diluted EPS (TTM) | -0.590 |
| Total Debt/Equity (MRQ) | 0.91% |
| Current Ratio (MRQ) | 10.96 |
| Operating Cash Flow (TTM) | -121.30 M |
| Levered Free Cash Flow (TTM) | -114.20 M |
| Return on Assets (TTM) | -28.29% |
| Return on Equity (TTM) | -45.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | ProKidney Corp. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.50 |
Select this tab to load the latest available analysis.
|
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 30.05% |
| % Held by Institutions | 42.03% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Artia Global Partners Lp | 30 Jun 2026 | 1,806,939 |
| Brown University | 30 Jun 2026 | 1,000,000 |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |